Effect of denosumab compared to risedronate on bone strength in patients initiating or continuing glucocorticoid treatment
This article is protected by copyright. All rights reserved. (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - March 26, 2022 Category: Orthopaedics Authors: Piet Geusens,
Melissa S.A.M. Bevers,
Bert van Rietbergen,
Osvaldo D. Messina,
Eric Lespessailles,
Beatriz Oliveri,
Roland Chapurlat,
Klaus Engelke,
Arkadi Chines,
Shuang Huang,
Kenneth G. Saag,
Joop P van den Bergh Tags: Clinical Trial Source Type: research
Improving Bone Mineral Density: Risedronate vs. Denosumab
Treatment with denosumab for patients with RA and glucocorticoid-induced osteoporosis led to greater increases in bone mineral density of the lumbar spine and hips of patients than treatment with risedronate. (Source: The Rheumatologist)
Source: The Rheumatologist - March 2, 2022 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: ACR Convergence Drug Updates Meeting Reports ACR Convergence 2021 bone mineral density (BMD) denosumab Glucocorticoids Osteoporosis risedronate Source Type: research
Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review
This meta-analysis and systematic review investigated the efficacy of bisphosphonates on the incidence of hip fracture (IHF) in patients of different ages with osteoporosis or osteopenia. We searched Web of Science, Embase, the Cochrane Database, and PubMed from inception to January 10, 2021, for trials reporting the effects of bisphosphonates on the IHF. We included only randomized, double-blind, placebo-controlled clinical trials. We pooled data using a random-effects meta-analysis with risk ratios (RRs) and reported 95% CIs. We also used the Cochran Q and I² statistics to assess the heterogeneity in the results of ...
Source: Journal of Investigative Medicine - February 25, 2022 Category: Research Authors: Zhao, S., Zhao, W., Du, D., Zhang, C., Zhao, T., Zheng, L., Jin, L., Gu, M., Xu, J., Yang, Z. Tags: Original research Source Type: research
Molecules, Vol. 27, Pages 1283: Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo- & beta;-Lactamase-1 (NDM-1): A Drug Repurposing Approach
Molecules, Vol. 27, Pages 1283: Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo-β-Lactamase-1 (NDM-1): A Drug Repurposing Approach
Molecules doi: 10.3390/molecules27041283
Authors:
Ghazala Muteeb
Abdulrahman Alsultan
Mohd Farhan
Mohammad Aatif
Bacteria expressing New Delhi metallo-β-lactamase-1 (NDM-1) can hydrolyze β-lactam antibiotics (penicillins, cephalosporins, and carbapenems) and, thus, mediate multidrug resistance. The worldwide dissemination of NDM-1 poses a serious threat to public health, imposing a huge economic burden in the develo...
Source: Molecules - February 14, 2022 Category: Chemistry Authors: Ghazala Muteeb Abdulrahman Alsultan Mohd Farhan Mohammad Aatif Tags: Article Source Type: research
The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis
ConclusionTRACP-5b is not affected by food intake, unlike CTX and PINP. All three BTMs correlate with change in BMD at the lumbar spine and total hip. TRACP-5b has similar diagnostic accuracy to CTX and PINP with commonly used treatments for osteoporosis with the exception of oral bisphosphonate therapy. (Source: Osteoporosis International)
Source: Osteoporosis International - January 31, 2022 Category: Orthopaedics Source Type: research
Calcium montmorillonite as potential carrier in release of bisphosphonates
New J. Chem., 2022, Accepted Manuscript DOI: 10.1039/D1NJ04268H, PaperMariusz Sandomierski, Monika Zieli ńska, Katarzyna Adamska, Adam Patalas, Adam Voelkel There is a strong need to search for more effective bisphosphonates carriers which will lead to increased bioavailability of bone tissue engineering. Montmorillonite and calcium montmorillonite were used as risedronate... The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - New J. Chem. latest articles)
Source: RSC - New J. Chem. latest articles - January 21, 2022 Category: Chemistry Authors: Mariusz Sandomierski Source Type: research
Importance of Time Point-Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses
This study was the first to investigate the impact of time point-specific NMAs of osteoporosis treatments on variability in treatments' onset of action caused by their different mechanisms of actions and trial designs.METHODS: A systematic literature review was conducted to identify randomized controlled trials (RCTs) of treatments for postmenopausal women with osteoporosis, including romosozumab (ROMO), teriparatide (TPTD), abaloparatide (ABL), alendronate (ALN), risedronate (RIS), ibandronate (IB), zoledronic acid/zoledronate (ZOL), denosumab (DEN), and raloxifene (RLX), on at least 1 fracture or bone mineral density (BM...
Source: Clinical Therapeutics - January 21, 2022 Category: Drugs & Pharmacology Authors: Damon Willems Muhammad Kassim Javaid Rafael Pinedo-Villanueva Cesar Libanati Alon Yehoshua Mata Charokopou Source Type: research
Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review
ConclusionsThe cost-effectiveness of denosumab for the treatment of osteoporosis was influenced by multiple factors. Generally, denosumab was more cost-effective in patients with older age, prior fracture experience, lower BMD T-scores, and more risk factors. ESCEO-IOF guidelines were more applicable to improve the transparency, generalization, and quality of pharmacoeconomic studies in osteoporosis. (Source: Osteoporosis International)
Source: Osteoporosis International - January 21, 2022 Category: Orthopaedics Source Type: research
Glucocorticoid-induced osteoporosis-Focus treatment (part 2)
Z Rheumatol. 2022 Jan 10. doi: 10.1007/s00393-021-01128-7. Online ahead of print.ABSTRACTThe following substances are approved for the treatment of glucocorticoid-induced osteoporosis: the oral bisphosphonates alendronate and risedronate, the intravenous bisphosphonate zoledronate, the RANKL antibody denosumab as antiresorptive substances and teriparatide as osteoanabolic substance. In comparison to placebo a reduction of vertebral fractures is proven for all mentioned substances. Thereby, teriparatide is more effective than alendronate and risedronate with respect to the reduction of vertebral fractures. The severity of o...
Source: Zeitschrift fur Rheumatologie - January 10, 2022 Category: Rheumatology Authors: Peter Oelzner T Eidner A Pfeil Source Type: research
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study
CONCLUSION: Drug holidays after long-term therapy with risedronate were associated with a small increase in risk for hip fracture compared with alendronate drug holidays. Future research should examine how best to mitigate this risk.PRIMARY FUNDING SOURCE: Canadian Institutes of Health Research.PMID:35007149 | DOI:10.7326/M21-2512 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 10, 2022 Category: Internal Medicine Authors: Kaleen N Hayes Kevin A Brown Angela M Cheung Sandra A Kim David N Juurlink Suzanne M Cadarette Source Type: research
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study
CONCLUSION: Drug holidays after long-term therapy with risedronate were associated with a small increase in risk for hip fracture compared with alendronate drug holidays. Future research should examine how best to mitigate this risk.PRIMARY FUNDING SOURCE: Canadian Institutes of Health Research.PMID:35007149 | DOI:10.7326/M21-2512 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 10, 2022 Category: Internal Medicine Authors: Kaleen N Hayes Kevin A Brown Angela M Cheung Sandra A Kim David N Juurlink Suzanne M Cadarette Source Type: research
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study
CONCLUSION: Drug holidays after long-term therapy with risedronate were associated with a small increase in risk for hip fracture compared with alendronate drug holidays. Future research should examine how best to mitigate this risk.PRIMARY FUNDING SOURCE: Canadian Institutes of Health Research.PMID:35007149 | DOI:10.7326/M21-2512 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 10, 2022 Category: Internal Medicine Authors: Kaleen N Hayes Kevin A Brown Angela M Cheung Sandra A Kim David N Juurlink Suzanne M Cadarette Source Type: research
